Iovance Biotherapeutics (NASDAQ:IOVA) Stock Breaks Below Fifty Day Moving Average – Here’s Why

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $11.38 and traded as low as $9.35. Iovance Biotherapeutics shares last traded at $9.56, with a volume of 58,772,732 shares.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with previously treated non-squamous mNSCLC, consistent with previously reported results. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched subgroup reached 59.1%, supporting further precision-medicine development. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: The company said IOV-LUN-202 enrollment is nearing completion and plans to use the results to support a supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. A biomarker-enriched registrational study, POSITILITY, is expected to begin enrollment in November 2026. Iovance Lung Cancer Strategy
• Positive Sentiment: Recent melanoma and other solid-tumor data, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, reinforced optimism about the broader lifileucel platform. Analysts at Zacks also upgraded IOVA to “strong buy.” Lifileucel Shows 50% Response Rate
• Neutral Sentiment: Options activity was elevated, with traders purchasing 28,173 call options—about 70% above typical daily call volume—indicating increased speculative interest ahead of the data and upcoming earnings report.
• Negative Sentiment: Despite the headline-positive results, investors focused on the overall 24.6% response rate and the sharp difference between biomarker-defined subgroups. The market reaction suggests concerns that the data may not demonstrate broad enough efficacy for lung-cancer expansion, or may require a narrower targeted population than previously expected. Iovance Stock Reaction to Lung Cancer Data
• Negative Sentiment: The sharp decline occurred on volume far above average, suggesting substantial investor repositioning rather than a minor market fluctuation. Upcoming earnings expectations for a quarterly loss remain an additional source of risk.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Zacks Research upgraded Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday. Robert W. Baird upped their price target on Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. TD Cowen increased their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Finally, The Goldman Sachs Group initiated coverage on Iovance Biotherapeutics in a research note on Thursday, September 24th. They set a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

Iovance Biotherapeutics Stock Down 35.4%

The company has a market capitalization of $4.33 billion, a PE ratio of -13.10 and a beta of 0.76. The stock has a 50-day moving average of $11.38 and a 200 day moving average of $5.79.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to analysts’ expectations of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The business’s revenue was up 65.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. Equities analysts forecast that Iovance Biotherapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in IOVA. KBC Group NV bought a new stake in shares of Iovance Biotherapeutics in the 1st quarter worth approximately $34,000. Sanctuary Advisors LLC bought a new position in Iovance Biotherapeutics during the first quarter valued at $38,000. Valley National Advisers Inc. bought a new position in Iovance Biotherapeutics during the third quarter valued at $38,000. Fifth Third Bancorp bought a new position in Iovance Biotherapeutics during the first quarter valued at $39,000. Finally, Ceera Investments LLC purchased a new stake in Iovance Biotherapeutics in the first quarter worth $44,000. Institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.